Inactive Instrument

Lidds AB Stock price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK 0.00% Intraday chart for Lidds AB
Sales 2021 3.55M 332K Sales 2022 1.89M 177K Capitalization 58.92M 5.51M
Net income 2021 -37M -3.46M Net income 2022 -36M -3.37M EV / Sales 2021 81.8 x
Net cash position 2021 34M 3.18M Net cash position 2022 1.26M 118K EV / Sales 2022 30.5 x
P/E ratio 2021
-8.2 x
P/E ratio 2022
-1.58 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 60.43%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 53 21-11-30
Corporate Officer/Principal - 22-09-30
Corporate Officer/Principal 61 03-12-31
Members of the board TitleAgeSince
Director/Board Member 62 Jan. 08
Director/Board Member 62 Jan. 08
Director/Board Member 49 18-12-31
More insiders
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Company's portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock LIDDS AB
  4. Stock Lidds AB - Nasdaq Stockholm